ArticleThe Kaohsiung journal of medical sciences2025
Monotropein Induced Ferroptosis to Alleviate the Progression of Hepatocellular Carcinoma via Regulating Nrf2/HO-1/GPX4 Axis.
Article in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monotropein Induced Ferroptosis to Alleviate the Progression of Hepatocellular Carcinoma via Regulating Nrf2/HO-1/GPX4 Axis.The Kaohsiung journal of medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) exhibits a high global morbidity rate and ranks as the fourth leading cause of cancer-related mortality worldwide. In response to the urgent need for effective HCC treatments, naturally occurring, botanical-driven compounds have gained increasing attention. Notably, the anti-tumor properties of some compounds might be linked to the induction of ferroptosis. The present study aimed to evaluate the capacity of Monotropein (Mon) to induce ferroptosis in HCC and elucidate its underlying mechanisms. First, Mon was found to play an anti-tumor role in HCC cells by inhibiting cell proliferation and invasion, elevated the expression of E-cadherin, and decreased N-cadherin and Vimentin expression. Furthermore, Mon activated ferroptosis in HCC cells, characterized by elevated levels of Fe
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.